Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1982 1
1984 3
1986 3
1987 5
1988 4
1989 9
1990 11
1991 3
1992 5
1993 4
1994 4
1995 5
1996 9
1997 18
1998 23
1999 10
2000 16
2001 30
2002 30
2003 20
2004 43
2005 43
2006 42
2007 40
2008 53
2009 51
2010 73
2011 77
2012 87
2013 100
2014 90
2015 131
2016 148
2017 137
2018 137
2019 153
2020 154
2021 149
2022 130
2023 150
2024 55

Text availability

Article attribute

Article type

Publication date

Search Results

1,993 results

Results by year

Filters applied: . Clear all
Page 1
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.
Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, Juan-Vidal O, Handzhiev S, Izumi H, Lee JS, Dziadziuszko R, Wolf J, Blackhall F, Reck M, Bustamante Alvarez J, Hummel HD, Dingemans AC, Sands J, Akamatsu H, Owonikoko TK, Ramalingam SS, Borghaei H, Johnson ML, Huang S, Mukherjee S, Minocha M, Jiang T, Martinez P, Anderson ES, Paz-Ares L; DeLLphi-301 Investigators. Ahn MJ, et al. N Engl J Med. 2023 Nov 30;389(22):2063-2075. doi: 10.1056/NEJMoa2307980. Epub 2023 Oct 20. N Engl J Med. 2023. PMID: 37861218 Clinical Trial.
Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial.
Goto K, Goto Y, Kubo T, Ninomiya K, Kim SW, Planchard D, Ahn MJ, Smit EF, de Langen AJ, Pérol M, Pons-Tostivint E, Novello S, Hayashi H, Shimizu J, Kim DW, Kuo CH, Yang JC, Pereira K, Cheng FC, Taguchi A, Cheng Y, Feng W, Tsuchihashi Z, Jänne PA. Goto K, et al. Among authors: ahn mj. J Clin Oncol. 2023 Nov 1;41(31):4852-4863. doi: 10.1200/JCO.23.01361. Epub 2023 Sep 11. J Clin Oncol. 2023. PMID: 37694347 Free PMC article. Clinical Trial.
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA; AURA3 Investigators. Mok TS, et al. Among authors: ahn m j. N Engl J Med. 2017 Feb 16;376(7):629-640. doi: 10.1056/NEJMoa1612674. Epub 2016 Dec 6. N Engl J Med. 2017. PMID: 27959700 Free PMC article. Clinical Trial.
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.
Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, Garcia Campelo MR, Kim DW, Griesinger F, Felip E, Califano R, Spira AI, Gettinger SN, Tiseo M, Lin HM, Liu Y, Vranceanu F, Niu H, Zhang P, Popat S. Camidge DR, et al. Among authors: ahn mj. J Thorac Oncol. 2021 Dec;16(12):2091-2108. doi: 10.1016/j.jtho.2021.07.035. Epub 2021 Sep 16. J Thorac Oncol. 2021. PMID: 34537440 Free article. Clinical Trial.
Bat ASC2 suppresses inflammasomes and ameliorates inflammatory diseases.
Ahn M, Chen VC, Rozario P, Ng WL, Kong PS, Sia WR, Kang AEZ, Su Q, Nguyen LH, Zhu F, Chan WOY, Tan CW, Cheong WS, Hey YY, Foo R, Guo F, Lim YT, Li X, Chia WN, Sobota RM, Fu NY, Irving AT, Wang LF. Ahn M, et al. Cell. 2023 May 11;186(10):2144-2159.e22. doi: 10.1016/j.cell.2023.03.036. Cell. 2023. PMID: 37172565
Pembrolizumab for the treatment of non-small-cell lung cancer.
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L; KEYNOTE-001 Investigators. Garon EB, et al. Among authors: ahn mj. N Engl J Med. 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824. Epub 2015 Apr 19. N Engl J Med. 2015. PMID: 25891174 Free article. Clinical Trial.
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ; KEYNOTE-040 investigators. Cohen EEW, et al. Among authors: ahn mj. Lancet. 2019 Jan 12;393(10167):156-167. doi: 10.1016/S0140-6736(18)31999-8. Epub 2018 Nov 30. Lancet. 2019. PMID: 30509740 Clinical Trial.
KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.
Lim TKH, Skoulidis F, Kerr KM, Ahn MJ, Kapp JR, Soares FA, Yatabe Y. Lim TKH, et al. Among authors: ahn mj. Lung Cancer. 2023 Oct;184:107293. doi: 10.1016/j.lungcan.2023.107293. Epub 2023 Jul 13. Lung Cancer. 2023. PMID: 37683526 Free article. Review.
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer.
Passaro A, Leighl N, Blackhall F, Popat S, Kerr K, Ahn MJ, Arcila ME, Arrieta O, Planchard D, de Marinis F, Dingemans AM, Dziadziuszko R, Faivre-Finn C, Feldman J, Felip E, Curigliano G, Herbst R, Jänne PA, John T, Mitsudomi T, Mok T, Normanno N, Paz-Ares L, Ramalingam S, Sequist L, Vansteenkiste J, Wistuba II, Wolf J, Wu YL, Yang SR, Yang JCH, Yatabe Y, Pentheroudakis G, Peters S. Passaro A, et al. Among authors: ahn mj. Ann Oncol. 2022 May;33(5):466-487. doi: 10.1016/j.annonc.2022.02.003. Epub 2022 Feb 14. Ann Oncol. 2022. PMID: 35176458 Free article.
1,993 results